| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. | J Hepatol | 2009 | 2.42 |
| 2 | Gene-expression signature of vascular invasion in hepatocellular carcinoma. | J Hepatol | 2011 | 2.39 |
| 3 | MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. | Gastroenterology | 2011 | 1.77 |
| 4 | IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. | J Hepatol | 2010 | 1.66 |
| 5 | Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. | Clin Cancer Res | 2012 | 1.44 |
| 6 | Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. | J Hepatol | 2012 | 1.26 |